1:05pm ET
Health and Healthcare
Multiple Sclerosis Treatment Wins Big FDA Approval
Biogen and Alkermes have announced that the FDA approved Vumerity for the treatment of relapsing forms of multiple sclerosis.
Companies
/Healthcare
Alkermes plc
$46.10
▼ $0.78 (−1.66%) today
Markets closed · 6:57pm ET
ALKS Coverage
Page 29:55am ET
Health and Healthcare
Alkermes Looks to Expand Its Schizophrenia Treatment to Bipolar Patients
Alkermes shares made a handy gain on Monday after the firm announced that it would be expanding its New Drug Application for ALKS 3831 to encompass the treatment of bipolar I disorder…
Chris Lange 9:05am ET
Investing
Top Analyst Upgrades and Downgrades: Agilent, Amazon, American Water Works, Crocs, Deere, GE, Gilead, Slack, Teva and More
The top analyst upgrades, downgrades and initiations on Monday included Agilent Technologies, Amazon.com, American Water Works, Crocs, Deere, General Electric, Gilead Sciences, Slack and Teva Pharmaceutical.
9:00am ET
Investing
Top Analyst Upgrades and Downgrades: Alkermes, Apple, Canada Goose, FireEye, J.Jill, Kraft Heinz, Uber, Vonage and More
The top analyst upgrades, downgrades and initiations seen on Friday included Alkermes, Apple, Canada Goose, FireEye, J.Jill, Kraft Heinz, Uber Technologies and Vonage.
9:00am ET
Investing
Top Analyst Upgrades and Downgrades: Alkermes, Alphabet, Apple, Conoco, FireEye, Lyft, McDonald’s, RBS, Seagate, Shopify and More
The top analyst upgrades, downgrades and initiations seen on Wednesday included Alkermes, Alphabet, Apple, ConocoPhillips, FireEye, Lyft, McDonald's, Royal Bank of Scotland, Seagate Technology and Shopify.
9:10am ET
Investing
Top Analyst Upgrades and Downgrades: Apple, Baker Hughes, Biogen, FedEx, Intel, Micron, Roku, Shake Shack and More
The top analyst upgrades, downgrades and initiations seen on Wednesday included Apple, Baker Hughes, Biogen, FedEx, Intel, Micron Technology, Roku and Shake Shack.
9:19am ET
Health and Healthcare
Why the FDA Is Dragging Alkermes Down
Alkermes shares dropped early on Friday after the company anncounced the results from its most recent meeting with the U.S. Food and Drug Administration.
Chris Lange 9:00am ET
Investing
Top Analyst Upgrades and Downgrades: Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts, Zillow and More
The top analyst upgrades, downgrades and other research calls from Tuesday include Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts and Zillow.
8:50am ET
Investing
Top Analyst Upgrades and Downgrades: Alkermes, Cigna, International Paper, Medtronic, Tesla, Western Digital and More
The top analyst upgrades, downgrades and other research calls from Wednesday include Alkermes, Cigna, International Paper, Medtronic, Tesla and Western Digital.
9:00am ET
Investing
Top Analyst Upgrades and Downgrades: AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp, Sarepta Therapeutics and More
The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp and Sarepta Therapeutics.
9:55am ET
Health and Healthcare
Alkermes Wins Big on FDA Approval
Shares of Alkermes saw a handy gain to start out the week after the FDA made a critical decision about its treatment for major depressive disorder.
Chris Lange 9:40am ET
Health and Healthcare
FDA Gets Down on Alkermes Depression Drug
Alkermes saw its shares drop early on Monday after the company announced that it received a Refusal to File letter from the FDA.
Chris Lange 9:14am ET
Investing
Top Analyst Upgrades and Downgrades: Alkermes, ArQule, Bluebird Bio, Cognizant, Ecolab, KLA-Tencor, Pandora, Verisk, Vonage and More
The top analyst upgrades, downgrades and other research calls from Thursday include Alkermes, ArQule, Bluebird Bio, Cognizant Technology Solutions, Ecolab, KLA-Tencor, Pandora Media, Verisk Analytics and Vonage.
8:55am ET
Health and Healthcare
20 More Biopharma Catalysts Coming in 2018
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
10:05am ET
Health and Healthcare
Alkermes Could Win Big With New Biogen Partnership
Alkermes saw its shares make a handy gain to start off the week, after the firm announced that it has entered into a global license agreement with Biogen.